JHL Biotech Raises $106 Million in Pre-IPO Funding

JHL Biotech, a China-Taiwan biosimilar company, placed $106 million in convertible bonds in a financing led by VMS Investment Group, a Hong Kong PE firm. The round was joined by existing shareholders. JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio. Earlier this year, JHL completed a voluntary de-listing of its Taiwan shares, a transaction that allowed shareholders to retain ownership of their holdings. The company is expected to conduct a $250 million IPO in Hong Kong later this year. More details....

Share this with colleagues:

Original Article: JHL Biotech Raises $106 Million in Pre-IPO Funding

More From BioPortfolio on "JHL Biotech Raises $106 Million in Pre-IPO Funding"